Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer

Nature Immunology

Volumn 18, Issue 8, 2017, Pages 940-950

  Ganesan, Anusha Preethi ^a,b   Clarke, James ^a,c   Wood, Oliver ^c   Garrido Martin, Eva M ^c   Chee, Serena J ^c,d   Mellows, Toby ^c   Samaniego Castruita, Daniela ^a   Singh, Divya ^a   Seumois, Grégory ^a   Alzetani, Aiman ^d   Woo, Edwin ^d   Friedmann, Peter S ^c   King, Emma V ^c   Thomas, Gareth J ^c   Sanchez Elsner, Tilman ^c   Vijayanand, Pandurangan ^a,c   Ottensmeier, Christian H ^c,d  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTEGRIN; ATM PROTEIN; CD103 ANTIGEN; CD137 ANTIGEN; CD27 ANTIGEN; CD45 ANTIGEN; CD69 ANTIGEN; CD8ALPHA ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR6; CYCLIN B1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INDUCIBLE T CELL COSTIMULATOR; INTEGRIN; INTEGRIN ALPHAEBETA7; KRUPPEL LIKE FACTOR 2; L SELECTIN; LAG3 PROTEIN; PEPTIDES AND PROTEINS; POLO LIKE KINASE 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN C JUN; SPHINGOSINE 1 PHOSPHATE RECEPTOR; STK38 PROTEIN; T LYMPHOCYTE RECEPTOR; TIGIT PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; ALPHA E INTEGRINS; ALPHA INTEGRIN; HAVCR2 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; PDCD1 PROTEIN, HUMAN;

ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DENSITY; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; MOLECULAR BIOLOGY; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; RNA SEQUENCE; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TISSUE RESIDENT MEMORY CELL; TRANSCRIPTOMICS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; ADENOCARCINOMA; ADULT; AGED; FEMALE; GENETICS; HEAD AND NECK TUMOR; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD137; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION PROFILING; HEAD AND NECK NEOPLASMS; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTEGRIN ALPHA CHAINS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 85025815252     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3775     Document Type: Article

References (62)

1. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
2. Drake, C.G., Lipson, E.J. &Brahmer, J.R. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat. Rev. Clin. Oncol. 11, 24-37 (2014).
3. Garon, E.B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
4. Sharma, P. &Allison, J.P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205-214 (2015).
5. Tumeh, P.C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
6. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
7. Yang, Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J. Clin. Invest. 125, 3335-3337 (2015).
8. Baitsch, L. et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J. Clin. Invest. 121, 2350-2360 (2011).
9. Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782-795 (2013).
10. Collins, N. et al. Transcriptional hallmarks of tumor infiltrating lymphocyte responses to melanoma. Blood 122, 3491 (2013).
11. Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189-196 (2016).
12. Pauken, K.E. &Wherry, E.J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 36, 265-276 (2015).
13. Brown, I.E., Blank, C., Kline, J., Kacha, A.K. &Gajewski, T.F. Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J. Immunol. 177, 4521-4529 (2006).
14. Montes, C.L. et al. Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion. Cancer Res. 68, 870-879 (2008).
15. Johnston, R.J. et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell 26, 923-937 (2014).
16. Curran, M.A. et al. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J. Exp. Med. 210, 743-755 (2013).
17. Willoughby, J.E. et al. Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunization. J. Immunol. 193, 244-251 (2014).
18. Topalian, S.L., Drake, C.G. &Pardoll, D.M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450-461 (2015).
19. Gros, A. et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246-2259 (2014).
20. Fourcade, J. et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 207, 2175-2186 (2010).
21. Wolfl, M. et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110, 201-210 (2007).
22. Wherry, E.J. et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27, 670-684 (2007).
23. Mackay, L.K. et al. The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin. Nat. Immunol. 14, 1294-1301 (2013).
24. Mueller, S.N., Gebhardt, T., Carbone, F.R. &Heath, W.R. Memory T cell subsets, migration patterns, and tissue residence. Annu. Rev. Immunol. 31, 137-161 (2013).
25. Mackay, L.K. et al. Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes. Science 352, 459-463 (2016).
26. Sathaliyawala, T. et al. Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity 38, 187-197 (2013).
27. Lee, L.N. et al. CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis. Infect. Immun. 79, 3328-3337 (2011).
28. Tse, S.W., Radtke, A.J., Espinosa, D.A., Cockburn, I.A. &Zavala, F. The chemokine receptor CXCR6 is required for the maintenance of liver memory CD8+ T cells specific for infectious pathogens. J. Infect. Dis. 210, 1508-1516 (2014).
29. Skon, C.N. et al. Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells. Nat. Immunol. 14, 1285-1293 (2013).
30. Ariotti, S. et al. T cell memory. Skin-resident memory CD8+ T cells trigger a state of tissue-wide pathogen alert. Science 346, 101-105 (2014).
31. Schenkel, J.M. et al. T cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science 346, 98-101 (2014).
32. Best, J.A. et al. Transcriptional insights into the CD8+ T cell response to infection and memory T cell formation. Nat. Immunol. 14, 404-412 (2013).
33. Bono, M.R., Fernández, D., Flores-Santibáñez, F., Rosemblatt, M. &Sauma, D. CD73 and CD39 ectonucleotidases in T cell differentiation: beyond immunosuppression. FEBS Lett. 589, 3454-3460 (2015).
34. Kuhny, M., Hochdörfer, T., Ayata, C.K., Idzko, M. &Huber, M. CD39 is a negative regulator of P2X7-mediated inflammatory cell death in mast cells. Cell Comm. Signal. 12, 40 (2014).
35. Ohta, A. A metabolic immune checkpoint: adenosine in tumor microenvironment. Front. Immunol. 7, 109 (2016).
36. Gupta, P.K. et al. CD39 expression identifies terminally exhausted CD8+ T cells. PLoS Pathog. 11, e1005177 (2015).
37. Sandoval-Montes, C. &Santos-Argumedo, L. CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokines. J. Leukoc. Biol. 77, 513-521 (2005).
38. Muñoz, P. et al. Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse. Blood 111, 3653-3664 (2008).
39. Hombrink, P. et al. Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells. Nat. Immunol. 17, 1467-1478 (2016).
40. Faure, M. &Long, E.O. KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential. J. Immunol. 168, 6208-6214 (2002).
41. Rajagopalan, S. &Long, E.O. KIR2DL4 (CD158d): an activation receptor for HLA-G. Front. Immunol. 3, 258 (2012).
42. Wiśniewski, A. et al. Genetic polymorphisms and expression of HLA-G and its receptors, KIR2DL4 and LILRB1, in non-small cell lung cancer. Tissue Antigens 85, 466-475 (2015).
43. Brooke, G., Holbrook, J.D., Brown, M.H. &Barclay, A.N. Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family. J. Immunol. 173, 2562-2570 (2004).
44. Piccio, L. et al. Adhesion of human T cells to antigen-presenting cells through SIRPbeta2-CD47 interaction costimulates T-cell proliferation. Blood 105, 2421-2427 (2005).
45. Wang, Z.Q. et al. CD103 and intratumoral immune response in breast cancer. Clinical Cancer Res. 22, 6290-6297 (2016).
46. Webb, J.R., Milne, K. &Nelson, B.H. Location, location, location: CD103 demarcates intraepithelial, prognostically favorable CD8+ tumor-infiltrating lymphocytes in ovarian cancer. OncoImmunology 3, e27668 (2014).
47. Djenidi, F. et al. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J. Immunol. 194, 3475-3486 (2015).
48. Kurachi, M. et al. The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells. Nat. Immunol. 15, 373-383 (2014).
49. Xin, G. et al. A critical role of IL-21-induced BATF in sustaining CD8-T-cell-mediated chronic viral control. Cell Rep. 13, 1118-1124 (2015).
50. Wolkers, M.C. et al. Nab2 regulates secondary CD8+ T-cell responses through control of TRAIL expression. Blood 119, 798-804 (2012).
51. Vijayanand, P. et al. Invariant natural killer T cells in asthma and chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 1410-1422 (2007).
52. Engel, I. et al. Innate-like functions of natural killer T cell subsets result from highly divergent gene programs. Nat. Immunol. 17, 728-739 (2016).
53. Marsh, D. et al. Stromal features are predictive of disease mortality in oral cancer patients. J. Pathol. 223, 470-481 (2011).
54. Ward, M.J. et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br. J. Cancer 110, 489-500 (2014).
55. Seumois, G. et al. Transcriptional profiling of Th2 cells identifies pathogenic features associated with asthma. J. Immunol. 197, 655-664 (2016).
56. Picelli, S. et al. Full-length RNA-seq from single cells using Smart-seq2. Nat. Protoc. 9, 171-181 (2014).
57. Trapnell, C., Pachter, L. &Salzberg, S.L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
58. Love, M.I., Huber, W. &Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
59. Bolotin, D.A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380-381 (2015).
60. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
61. Safford, M. et al. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat. Immunol. 6, 472-480 (2005).
62. Fridman, A.L. &Tainsky, M.A. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 27, 5975-5987 (2008).